Furosemide Use in Chronic Kidney Disease

Indications and Contraindications

Furosemide should be used in CKD patients primarily for the management of volume overload, not for prevention of acute kidney injury or as routine therapy without volume overload, as recommended by the Kidney International guidelines 1
The Kidney International guidelines recommend that furosemide is indicated for the treatment of volume overload in CKD patients, not for prevention of AKI 1
Furosemide is contraindicated for prevention of AKI in CKD patients, and should be avoided in severely volume-depleted or hypotensive patients, according to the Kidney International guidelines 1

Oral administration is preferred in stable CKD patients due to good bioavailability, as stated by the Hepatology guidelines 2, 3
The British Journal of Pharmacology recommends checking renal function and electrolytes at baseline, and rechecking 1-2 weeks after initiation or dose change, and monitoring more frequently in advanced CKD (stages 4-5) 4
The British Journal of Pharmacology also recommends continuing monitoring every 4 months when stable, and monitoring serum potassium closely, especially when combined with RAS inhibitors 4, 5

For CKD patients with cirrhotic ascites, the Hepatology guidelines recommend using furosemide in combination with spironolactone (typically 40 mg furosemide:100 mg spironolactone ratio) 2, 6
The Hepatology guidelines also recommend titrating doses every 3-5 days while maintaining the ratio to achieve adequate natriuresis, with maximum doses typically 160 mg/day furosemide and 400 mg/day spironolactone 2

The American Journal of Kidney Diseases guidelines recommend using furosemide with caution when combined with aminoglycosides due to increased nephrotoxicity risk, and monitoring for ototoxicity risk, especially with high doses or rapid IV administration 7
The Kidney International guidelines also recommend using furosemide with caution when combined with aminoglycosides due to increased nephrotoxicity risk 1, 7